Table 4:

Comparisons of outcomes of studies on ART initiation in HIV-TB co-infected persons

								Mortality / Serious Adverse Event
	Baseline CD4		Sample	Days to ART start		Mortality/ AIDS-defining Illness
								attributed to:
Study	cells/μL		size	(median, IQR)		incidence rate /100person-yr
								N(%)
	Inclusion	Median	N	Early	Delayed	Early	Delayed	Cryptococcus	Kaposi’s sarcoma
CAMELIA[4]	<200	25	661	14 (14–15)	56(56–57)	8.28	13.77	10 (1.5)	0 (0)
SAPIT[5]	<500	150	429	21(15–29)	97(77–126)	6.9	7.8	6 (1.4)	1 (0.2)
STRIDE[3]	<250	77	809	10 (7–12)	70(66–75)	12.9**	16.9**	13 (1.6)	11 (1.4)
					28(21–45)†		11†
TBHAART[13]	<200	72	478	7(4–48)		19		6 (1.3)	0 (0)
					56(48–75)		7
TBHAART[22]	>220	367	1675	<14*	≤56*	8.5**	7.9**	-	5 (0.3)
TIME[14]	<350	43	156	<28*	28–56*	8.76	7.25	9 (5.8)	1 (0.6)
Present study	<=100	24	377	14 (14–16)	44 (29–60)	32.7	25.2	7 (10.1)	5 (7.2)

ART=Antiretroviral therapy; TB=tuberculosis;

^*exact duration not specified

^**composite mortality/AIDS-defining illnesses

^†ART was started at two time points (4 weeks and 8 weeks after TB treatment start) during the Delayed ART period.